title: Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics.
abstract: Past reports have suggested that antiphospholipid (aPL) antibodies may emerge as a response to antipsychotics treatment, as a high prevalence of aPL antibodies in antipsychotics users has been observed. However, no control group of non-medicated psychiatric patients was included in these reports. In a cross sectional study we determined the prevalence of aPL antibodies in 333 psychiatric inpatients. We compared the proportions of positive aPL antibodytests between users and non-users of antipsychotics with adjustments for potential confounders. The proportion of antipsychotics users carrying at least one aPL antibody ranged from 10·8% to 27·0% compared with 6·8% to 27·2% in non-users (P = 0·24, P = 0·24) depending on the method of detection of lupus anticoagulant (LA). The prevalence of LA detected by dilute Russell viper venom time or partial thromboplastin time-LA was not different between antipsychotics users and non-users (8·1% vs. 5·4%, P = 0·53 and 18·4% vs. 18·2%, P = 0·22), as well as the prevalence of IgM and IgG anti-β2-glycoprotein-I antibodies, IgM and IgG anti-cardiolipin antibodies(3·8% vs. 2·0%, P = 0·75, 0·0% vs. 0·0%, P = not applicable, 1·1 vs. 1·4%, P = 0·91, 2·7% vs. 3·4%, P = 0·71). In conclusion, aPL antibodies were frequently found in patients with psychiatric diseases and no significant increase in the prevalence of aPL antibodies was observed in antipsychotics users.
authors.affiliation: Université de Bretagne Occidentale, EA 3878 (GETBO), Brest, France; Département de Médecine Interne et Pneumologie, CHRU Brest, Brest, France.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Delluc
authors.forename: Aurélie
authors.initials: A
authors.lastname: Rousseau
authors.forename: Mickael
authors.initials: M
authors.lastname: Le Galudec
authors.forename: Olivier
authors.initials: O
authors.lastname: Canceil
authors.forename: Barry
authors.initials: B
authors.lastname: Woodhams
authors.forename: Sylvie
authors.initials: S
authors.lastname: Etienne
authors.forename: Michel
authors.initials: M
authors.lastname: Walter
authors.forename: Dominique
authors.initials: D
authors.lastname: Mottier
authors.forename: Patrick
authors.initials: P
authors.lastname: Van Dreden
authors.forename: Karine
authors.initials: K
authors.lastname: Lacut
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011618:Psychotic Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D016036:Seroepidemiologic Studies; D055815:Young Adult
chemical_list: D017152:Antibodies, Antiphospholipid; D014150:Antipsychotic Agents
keywords: antiphospholipid antibodies; antipsychotics